PSA screening caused prostate cancer mortality to fall by 21%, demonstrated in the 13-year follow-up of the European Randomised Study of Screening for Prostate Cancer (ERSPC), indicating that early diagnosis and treatment of prostate cancer were indeed significantly improved by the popularity of serum PSA screening [14,15,16]. Here, KLK3 is linked to prostate carcinoma.